[go: up one dir, main page]

PE20141973A1 - Compuestos de heterociclilo como inhibidores de mek - Google Patents

Compuestos de heterociclilo como inhibidores de mek

Info

Publication number
PE20141973A1
PE20141973A1 PE2014001399A PE2014001399A PE20141973A1 PE 20141973 A1 PE20141973 A1 PE 20141973A1 PE 2014001399 A PE2014001399 A PE 2014001399A PE 2014001399 A PE2014001399 A PE 2014001399A PE 20141973 A1 PE20141973 A1 PE 20141973A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
compounds
mek inhibitors
tetrahydropyride
Prior art date
Application number
PE2014001399A
Other languages
English (en)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141973(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PE20141973A1 publication Critical patent/PE20141973A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE R1 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; R2 ES -C(=O)N(R8)R9, ENTRE OTROS, EN DONDE R8 Y R9 SON CADA UNO H, CICLOALQUILO, HETEROCICLILO, ENTRE OTROS; R3 ES H, ALQUILO O CICLOALQUILO; R4 ES H, HALOGENO, ALQUILO O CICLOALQUILO; R5 ES ARILO OPCIONALMENTE SUSTITUIDO CON Ra Y Rb, EN DONDE Ra Y Rb SON CADA UNO H, HALOGENO O HALOALQUILO. SON COMPUESTOS PREFERIDOS: 3-(3-(5-((2-FLUORO-4-YODOFENIL)AMINO)-6,8-DIMETIL-2,4,7-TRIOXO-3,4,6,7-TETRAHIDROPIRIDO[4,3-d]PIRIMIDIN-1(2H)-IL)FENIL)PROPANAMIDA; N-CICLOPROPIL-3-(5-((2-FLUORO-4-YODOFENIL)AMINO)-6,8-DIMETIL-2,4,7-TRIOXO-3,4,6,7-TETRAHIDROPIRIDO[4,3-d]PIRIMIDIN-1(2H)-IL)BENZAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA MEK SIENDO UTILES EN EL TRATAMIENTO DE CANCER, PSORIASIS, RESTENOSIS
PE2014001399A 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek PE20141973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14

Publications (1)

Publication Number Publication Date
PE20141973A1 true PE20141973A1 (es) 2014-12-12

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014001400A PE20141974A1 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo
PE2014001399A PE20141973A1 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de mek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014001400A PE20141974A1 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo

Country Status (35)

Country Link
US (5) US9428499B2 (es)
EP (2) EP2834236B1 (es)
JP (3) JP6093384B2 (es)
KR (4) KR102240101B1 (es)
CN (4) CN104271577A (es)
AP (2) AP3834A (es)
AU (4) AU2013234014B2 (es)
BR (1) BR112014022713B1 (es)
CA (2) CA2865167C (es)
CL (2) CL2014002412A1 (es)
CO (2) CO7170131A2 (es)
CR (2) CR20140463A (es)
CU (2) CU24272B1 (es)
DK (2) DK2834237T3 (es)
DO (2) DOP2014000204A (es)
EA (2) EA028232B1 (es)
ES (2) ES2684517T3 (es)
GE (2) GEP201706774B (es)
GT (2) GT201400196A (es)
IL (2) IL234559A (es)
IN (2) IN2014MN01754A (es)
MA (2) MA37405A1 (es)
MX (3) MX355474B (es)
MY (2) MY174188A (es)
NI (2) NI201400107A (es)
NZ (2) NZ629442A (es)
PE (2) PE20141974A1 (es)
PH (2) PH12014502041A1 (es)
PL (1) PL2834237T3 (es)
SG (2) SG11201405007QA (es)
TN (2) TN2014000356A1 (es)
TR (1) TR201811976T4 (es)
UA (2) UA114907C2 (es)
WO (2) WO2013136254A1 (es)
ZA (1) ZA201406186B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TR201811976T4 (tr) 2012-03-14 2018-09-21 Lupin Ltd Mek inhibitörleri olarak heterosiklil bileşikleri.
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
RU2667892C2 (ru) * 2013-10-25 2018-09-25 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные пиридилкетона, способ их получения и их фармацевтическое применение
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN110167928A (zh) 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10829487B2 (en) 2017-12-21 2020-11-10 Boehringer Ingelheim International Gmbh Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022537044A (ja) 2019-06-19 2022-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん併用療法
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022001328A (es) * 2019-07-30 2022-05-20 Edvince Ab Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3183656A1 (en) * 2020-06-02 2021-12-09 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2022214594A1 (en) 2021-04-09 2022-10-13 Boehringer Ingelheim International Gmbh Anticancer therapy
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
EP4323066A1 (en) * 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN119013272A (zh) 2021-12-01 2024-11-22 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
CN118613485A (zh) 2021-12-01 2024-09-06 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
US20250129096A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
JP2024047569A (ja) * 2022-09-26 2024-04-05 ファイザー・インク Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
PL220952B1 (pl) * 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
UA84175C2 (ru) 2003-11-19 2008-09-25 Аррей Байофарма Инк. Гетероциклические ингибиторы мэк и их применение
EP1761528B1 (en) * 2004-06-11 2008-01-09 Japan Tobacco, Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN102458580A (zh) 2009-04-21 2012-05-16 诺瓦提斯公司 作为mek抑制剂的杂环化合物
TR201811976T4 (tr) 2012-03-14 2018-09-21 Lupin Ltd Mek inhibitörleri olarak heterosiklil bileşikleri.

Also Published As

Publication number Publication date
NI201400108A (es) 2014-11-28
DK2834236T3 (da) 2019-08-26
BR112014022713A2 (es) 2017-06-20
KR102240101B1 (ko) 2021-04-14
UA114906C2 (uk) 2017-08-28
EA029768B1 (ru) 2018-05-31
NI201400107A (es) 2014-11-26
PL2834237T3 (pl) 2018-11-30
PH12014502041B1 (en) 2014-11-24
NZ629442A (en) 2016-12-23
US9555035B2 (en) 2017-01-31
US9827247B2 (en) 2017-11-28
JP2018115215A (ja) 2018-07-26
ZA201406186B (en) 2016-06-29
KR20140138910A (ko) 2014-12-04
TR201811976T4 (tr) 2018-09-21
EP2834237A1 (en) 2015-02-11
EA028232B1 (ru) 2017-10-31
JP6630771B2 (ja) 2020-01-15
IN2014MN01755A (es) 2015-07-03
EP2834236A1 (en) 2015-02-11
AU2013234014A1 (en) 2014-09-25
US9573944B2 (en) 2017-02-21
CA2865167C (en) 2019-08-06
ES2684517T3 (es) 2018-10-03
MA37400B1 (fr) 2019-11-29
CN107698585A (zh) 2018-02-16
CN108383836B (zh) 2021-11-12
PH12014502040B1 (en) 2014-11-24
DK2834237T3 (en) 2018-08-27
AP3834A (en) 2016-09-30
SG11201405007QA (en) 2014-10-30
MX355474B (es) 2018-04-16
CL2014002412A1 (es) 2015-03-06
IN2014MN01754A (es) 2015-07-03
JP2015509975A (ja) 2015-04-02
CN108383836A (zh) 2018-08-10
UA114907C2 (uk) 2017-08-28
NZ629432A (en) 2017-01-27
JP6093384B2 (ja) 2017-03-08
BR112014022713B1 (pt) 2021-09-08
CA2865167A1 (en) 2013-09-19
KR102241111B1 (ko) 2021-04-15
CA2865164C (en) 2021-06-08
TN2014000357A1 (en) 2015-12-21
KR20190073597A (ko) 2019-06-26
HK1206020A1 (en) 2015-12-31
WO2013136254A1 (en) 2013-09-19
CA2865164A1 (en) 2013-09-19
PH12014502041A1 (en) 2014-11-24
CR20140464A (es) 2014-11-28
US9428499B2 (en) 2016-08-30
US20160331753A1 (en) 2016-11-17
JP2015514056A (ja) 2015-05-18
US20150133424A1 (en) 2015-05-14
GT201400196A (es) 2017-09-28
SG11201405006PA (en) 2014-10-30
AU2013234014B2 (en) 2017-02-02
AP2014008009A0 (en) 2014-10-31
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
AU2017200493B2 (en) 2018-03-29
CN104203947A (zh) 2014-12-10
EA201491671A1 (ru) 2014-12-30
US20170101408A1 (en) 2017-04-13
MY174188A (en) 2020-03-12
AU2013234009A1 (en) 2014-09-25
GEP201706671B (en) 2017-05-25
US20150299186A1 (en) 2015-10-22
CU20140109A7 (es) 2014-11-27
DOP2014000204A (es) 2015-02-15
ES2741896T3 (es) 2020-02-12
AU2018202568B2 (en) 2019-05-09
CU20140110A7 (es) 2014-11-27
AU2017200493A1 (en) 2017-02-16
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
AU2018202568A1 (en) 2018-05-10
US9969731B2 (en) 2018-05-15
MX366426B (es) 2019-07-08
CU24335B1 (es) 2018-04-03
MA37400A1 (fr) 2016-05-31
US20170112840A1 (en) 2017-04-27
PH12014502040A1 (en) 2014-11-24
EP2834237B1 (en) 2018-06-06
WO2013136249A1 (en) 2013-09-19
DOP2014000203A (es) 2015-02-15
MX355526B (es) 2018-04-20
IL234559A (en) 2017-06-29
GT201400195A (es) 2017-11-09
PE20141974A1 (es) 2014-12-12
CN104271577A (zh) 2015-01-07
KR20140138911A (ko) 2014-12-04
MX2014010928A (es) 2015-04-10
GEP201706774B (en) 2017-11-27
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
MA37405A1 (fr) 2016-03-31
EP2834236B1 (en) 2019-05-22
JP6431770B2 (ja) 2018-11-28
CO7170131A2 (es) 2015-01-28
AP3859A (en) 2016-10-31
KR20190100472A (ko) 2019-08-28
AP2014008008A0 (en) 2014-10-31
AU2013234009B2 (en) 2016-10-27
CL2014002411A1 (es) 2015-04-06
MX2014010925A (es) 2015-04-10
IL234560A (en) 2017-06-29
CU24272B1 (es) 2017-08-08

Similar Documents

Publication Publication Date Title
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20091408A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20161443A1 (es) Compuestos
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
PE20121327A1 (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
MX386187B (es) Compuestos de benzo[b]tiofeno como agonistas de sting.
PE20121482A1 (es) Derivados de imidazopiridina como inhibidores de jak
PE20110411A1 (es) Imidazopiridazinacarbonitrilos como inhibidores de quinasa
PE20160875A1 (es) Compuestos de biaril-amida como inhibidores de cinasa
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
UY35012A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20161246A1 (es) Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinilo
AR095347A1 (es) Compuestos orgánicos
PE20131343A1 (es) Derivados de acido benzoico
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
UY36226A (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.

Legal Events

Date Code Title Description
FG Grant, registration